A PCV2 vaccine and a method of vaccinating against PCV2 are provided herein. The PCV2 vaccine includes a PCV2 infectious clone with a re-engineered PCV2 capsid in the backbone thereof, wherein the re-engineered PCV2 capsid includes a modified immunogenic region. The method of vaccinating against PCV2 includes administering the PCV2 vaccine including a PCV2 infectious clone with a re-engineered PCV2 capsid in the backbone thereof to a subject in need thereof.

The invention relates to a novel porcine circovirus type 2 (PCV2) strain. The invention also relates to immunogenic compositions containing the novel PCV2 strain, PCV2 test kits, and applications of the novel PCV2 strain.

A new species of circovirus, porcine circovirus type 3 (PCV3), was identified from sows with clinical symptoms normally associated with porcine circovirus type 2 (PCV2) infection and in aborted fetuses. Molecular and serological analyses suggest PCV3 commonly circulates in U.S. swine. The present disclosure provides immunological compositions and methods related to the production and administration of such compositions.

A new species of circovirus, porcine circovirus type 3 (PCV3), was identified from sows with clinical symptoms normally associated with porcine circovirus type 2 (PCV2) infection and in aborted fetuses. Molecular and serological analyses suggest PCV3 commonly circulates in U.S. swine. The present disclosure provides immunological compositions and methods related to the production and administration of such compositions.

The invention pertains to a combination of a first vaccine comprising anon-replicating immunogen of porcine circovirus type 2 (PCV-2) and a non-replicating immunogen of Mycoplasma hyopneumoniae, and a second vaccine comprising a live attenuated porcine reproductive and respiratory syndrome (PRRS) virus, for use in prophylactically treating a pig against an infection with PCV-2, an infection with Mycoplasma hyopneumoniae and an infection with PRRS virus, by associated separate injection of the first vaccine and the second vaccine into a tissue of the pig at a first and a second injection site respectively, wherein the first and second injection sites are at most 5 cm apart from each other.

A new species of circovirus, porcine circovirus type 3 (PCV3), was identified from sows with clinical symptoms normally associated with porcine circovirus type 2 (PCV2) infection and in aborted fetuses. Molecular and serological analyses suggest PCV3 commonly circulates in U.S. swine. The present disclosure provides immunological compositions and methods related to the production and administration of such compositions.

A new species of circovirus, porcine circovirus type 3 (PCV3), was identified from sows with clinical symptoms normally associated with porcine circovirus type 2 (PCV2) infection and in aborted fetuses. Molecular and serological analyses suggest PCV3 commonly circulates in U.S. swine. The present disclosure provides immunological compositions and methods related to the production and administration of such compositions.

A new species of circovirus, porcine circovirus type 3 (PCV3), was identified from sows with clinical symptoms normally associated with porcine circovirus type 2 (PCV2) infection and in aborted fetuses. Molecular and serological analyses suggest PCV3 commonly circulates in U.S. swine. The present disclosure provides immunological compositions and methods related to the production and administration of such compositions.

A porcine circovirus type 3 virus strain and a vaccine composition prepared from the immunogenic substance of the strain are described. The porcine circovirus type 3 virus strain has good immunogenicity, and the prepared vaccine composition can provide complete protection against varies of porcine circovirus type 3 viruses from different sources.

This invention provides a Mycoplasma hyopneumoniae (M.hyo) antigen that is compatible with antigens from other swine pathogens, wherein the M.hyo antigen is a cell free M.hyo culture supernatant which is substantially free of swine IgG.